Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 4, Issue 1-2, Pages 7-10
http://dx.doi.org/10.1155/S1357714X00000025

Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-Based Chemotherapy

1Department of Oncology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
2Department of The National Unit of Orthopedic Oncology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Departments of Pathology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
4Departments of Radiology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Copyright © 2000 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Ofer Merimsky, Isaac Meller, Yehuda Kollender, Josephine Issakov, Gideon Flusser, and Moshe Inbar, “Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-Based Chemotherapy,” Sarcoma, vol. 4, no. 1-2, pp. 7-10, 2000. https://doi.org/10.1155/S1357714X00000025.